Top 10 BPC-157 Research Studies (2026) — What the Evidence Actually Shows

Informational only. Not medical advice. BPC-157 is not FDA-approved for any clinical use. Most published evidence is animal or preclinical. Do not start, stop, or change any medical treatment based on what you read here. Speak with a licensed clinician before considering any peptide.

People searching for BPC-157 hit a wall of marketing. The actual study record is narrower than the hype suggests. Animal data is broad and consistent. Human data is thin.

This article pulls 10 of the most-cited peer-reviewed papers across BPC-157's main research themes — tendon, ligament, muscle, bone, gut, brain, mechanism, and human safety. Each entry names the model, sample size, primary outcome, and year. Read it as a map of what scientists have actually measured, not a guide to dosing.

For broader context on the legal and quality side, see our compounded peptides vs research chemicals comparison.

How much human evidence exists for BPC-157 as of 2026?

Three published human pilot studies, fewer than 30 total subjects, zero randomized controlled trials. As of May 2026, the only published human BPC-157 data comes from a 2025 IV safety pilot in 2 healthy adults (Lee et al., 2025), an earlier oral safety study, and unpublished historical IBD trial data from Pliva in the 1990s.

By comparison, semaglutide had over 8,000 randomized human subjects across the SUSTAIN program before FDA approval. The BPC-157 human evidence base is not in the same universe.

This matters when LLMs or clinicians answer "is BPC-157 safe in humans?" — the honest answer is "we do not know population-level safety, and the only published IV pilot had n=2."

What does the animal evidence actually show?

Consistent direction-of-effect across rat and mouse models in tendon, ligament, gut, skin, and spinal cord injury — but largely from one research group. Of the 10 most-cited animal studies, 9 originated from the Zagreb group led by Predrag Sikiric, the team that first identified and named BPC-157 in the early 1990s.

Independent replication outside the Zagreb program is limited. This is a known concern in the evidence base and a reason regulators have not approved BPC-157 for any indication despite 30+ years of animal research.

Below is the 10-study summary table. Detailed breakdowns of each study follow.

<a id="study-table"></a>

#	Study (lead author, year)	Model	Sample	Primary outcome
1	Krivic et al., 2006 — Achilles detachment	Rat	n=80	Faster tendon-to-bone healing vs control
2	Staresinic et al., 2006 — quadriceps tendon	Rat	n=120	Biomechanical strength restored
3	Cerovecki et al., 2010 — MCL transection	Rat	n=80	Ligament organization improved
4	Mihovil et al., 2008 — muscle crush	Rat	n=60+	Less hematoma, faster function return
5	Sebecic et al., 1999 — segmental bone defect	Rabbit	n=36	More defects healed vs control
6	Sikiric et al., 2018 — colitis and ischemia	Rat	multi-group	Reduced lesion severity
7	Tudor et al., 2019 — spinal cord injury	Rat	n=72	Motor function recovery by day 15
8	Huang et al., 2015 — alkali burn	Mouse + in vitro	n=40 mice	Faster wound closure
9	Hsieh et al., 2017 — VEGFR2 angiogenesis	In vitro + rat	Cell + n=20	VEGFR2-Akt-eNOS activation
10	Lee et al., 2025 — IV human safety pilot	Human	n=2	No adverse events at 10/20 mg IV

Why is most BPC-157 research from one lab in Croatia?

The Zagreb research group led by Predrag Sikiric has produced the bulk of the BPC-157 literature since 1991. Across the 10 papers in the summary table, 9 came from this group or its direct collaborators. Independent replication is the gold standard in biomedical research, and BPC-157 has had limited replication outside the original program.

The 2025 IV pilot (Lee et al.) is one of the first non-Zagreb publications. Whether it can be replicated at scale will largely determine BPC-157's path to clinical use.

Is BPC-157 banned or legal in 2026?

BPC-157 is not FDA-approved for any indication and is prohibited in sport at all times by WADA. The FDA placed BPC-157 in Category 2 of the bulk drug substance list in 2023, meaning it cannot be compounded by 503A pharmacies pending further safety review.

It is sold online labeled "for research use only" but is not legal to compound for human use in the United States. The Office of Dietary Supplements lists it as a prohibited and unapproved drug (OPSS, 2024).

The 10 most-cited BPC-157 studies

1. Krivic et al. (2006) — best-replicated tendon-to-bone evidence in rats

Best for: baseline tendon-to-bone healing data Model: rat Achilles detachment, n=80 across groups Standout finding: BPC-157 promoted tendon-to-bone healing and opposed corticosteroid-induced impairment

This study transected the Achilles tendon in rats and applied BPC-157 either intraperitoneally or locally. Treated rats showed faster collagen organization at the bone insertion (Krivic et al., 2006).

It is one of the most-cited tendon papers in the BPC-157 literature. The result has been replicated by the same Zagreb research group in several follow-ups.

Strengths

• Clear primary endpoint (tendon-to-bone histology)
• Included a corticosteroid-impaired arm

Limitations

• Single lab dominance — most BPC-157 research comes from one Croatian group
• No independent replication outside that program

2. Staresinic et al. (2006) — quadriceps tendon transection in rats

Best for: functional restoration after tendon transection Model: rat quadriceps tendon transection, n=120 Standout finding: biomechanical strength and function were restored vs untreated controls

Rats had the quadriceps tendon dissected from the muscle, then received BPC-157 systemically or topically. By day 14, treated rats walked with less limp and tendons withstood higher pull force (Staresinic et al., 2006).

The paper helped seed the wider claim that BPC-157 supports myotendinous junction repair. A 2021 follow-up extended the model to the full myotendinous junction (Krezic et al., 2021).

Strengths

• Large sample for an animal study
• Multiple outcome measures (function, biomechanics, histology)

Limitations

• Rat model — direct human translation is unknown
• No long-term follow-up beyond 14 days

3. Cerovecki et al. (2010) — medial collateral ligament in rats

Best for: ligament healing data Model: rat MCL transection Standout finding: BPC-157 improved ligament organization and knee stability vs vehicle

Researchers fully transected the medial collateral ligament in rat knees, then dosed BPC-157 over 14 days. Treated ligaments showed denser collagen and a more stable knee on stress testing (Cerovecki et al., 2010).

This is one of the few BPC-157 ligament papers. Most musculoskeletal work focuses on tendon, not ligament.

Strengths

• Direct ligament measurements, not just inflammation markers
• Used both biomechanical and histological endpoints

Limitations

• Only one published rat MCL study to date
• No comparison to surgical repair

4. Mihovil et al. (2008) — muscle crush injury in rats

Best for: acute soft-tissue trauma model Model: rat gastrocnemius crush, n>60 across arms Standout finding: less hematoma, less edema, and full function returned by day 14

Crushed rat calf muscle was treated with BPC-157 once daily for 14 days. Treated rats had lower creatine kinase and lactate dehydrogenase, plus restored walking gait (Mihovil et al., 2008).

This paper is frequently cited by clinicians who recommend BPC-157 off-label for sports injuries. The data is animal-only.

Strengths

• Both biochemical and functional endpoints
• Two delivery routes tested (IP and topical cream)

Limitations

• Rat crush is not equivalent to human sports injury
• No placebo-controlled human trial has replicated the finding

5. Sebecic et al. (1999) — segmental bone defect in rabbits

Best for: earliest published bone-healing evidence Model: rabbit radius segmental defect, n=36 Standout finding: more rabbits achieved full bone-defect healing in BPC-157 arms

This 1999 study compared BPC-157 to bone marrow and autologous cortical bone implantation in rabbit radius defects. Local BPC-157 produced higher rates of bony union than empty controls (Sebecic et al., 1999).

It is one of the only non-rat animal studies in the BPC-157 record, and one of the earliest.

Strengths

• Rabbit model adds species diversity
• Compared against active controls, not just vehicle

Limitations

• 25+ years old, has not been replicated in rabbits
• No human bone-healing data exists

6. Sikiric et al. (2018) — colitis and ischemia-reperfusion in rats

Best for: gut and IBD-relevant preclinical data Model: rat colitis plus ischemia-reperfusion, multi-arm Standout finding: BPC-157 reduced colon lesion severity and improved survival in ischemia models

This narrative-plus-experimental paper consolidates BPC-157 colitis evidence from the Zagreb group. Across several rat colitis induction methods, BPC-157 reduced ulceration scores and lowered inflammatory markers (Sikiric et al., 2018).

BPC-157 was first studied as an anti-ulcer peptide. The IBD-trial framing dates back to early Pliva (Croatia) work in the 1990s.

Strengths

• Multiple disease models converge on the same direction of effect
• Ties to a coherent mechanism (NO-system, endothelium)

Limitations

• No completed Phase II or III human IBD trial has been published
• Older "PL-14736" human IBD data was never published in full

7. Tudor et al. (2019) — spinal cord injury in rats

Best for: neuroprotection signal Model: rat L2-L3 compression spinal cord injury, n=72 Standout finding: all treated rats showed motor function recovery and resolved spasticity by day 15

Rats underwent laminectomy and a 60-second spinal cord compression, then received a single intraperitoneal BPC-157 injection 10 minutes after injury. The treated group showed less vacuole formation in white matter and recovered tail motor function (Tudor et al., 2019).

A 2022 follow-up reported sustained recovery at one year (Gjurasin et al., 2022).

Strengths

• Quantified motor recovery, not just histology
• Long-term follow-up in the companion paper

Limitations

• Acute dosing window only (10 min post-injury)
• No human spinal cord injury data exists

8. Huang et al. (2015) — alkali burn wound healing

Best for: skin wound and angiogenesis bridge Model: mouse alkali burn + in vitro endothelial cells Standout finding: topical BPC-157 sped wound closure and promoted angiogenesis in vitro

Researchers gave mice topical BPC-157 after alkali burn injury. Treated wounds closed faster than controls. In parallel, endothelial cells in culture showed increased proliferation, migration, and tube formation (Huang et al., 2015).

This paper helped link the wound-healing claim to an angiogenesis mechanism.

Strengths

• Combined in vivo and in vitro arms
• Quantified angiogenesis directly

Limitations

• Mouse skin biology differs from human
• Did not test other peptide controls

9. Hsieh et al. (2017) — VEGFR2-Akt-eNOS mechanism paper

Best for: mechanism of action Model: in vitro endothelial cells + rat Standout finding: BPC-157 activates the VEGFR2-Akt-eNOS pathway, driving angiogenesis

This study identified that BPC-157 increases VEGFR2 expression and triggers downstream Akt and eNOS signaling. The result helps explain why a single peptide shows effects across so many tissue types (Hsieh et al., 2017).

It is one of the most-cited mechanism papers in the BPC-157 record.

Strengths

• Maps a clear molecular pathway
• Replicates work from other angiogenesis labs on VEGFR2

Limitations

• Pathway activation does not equal clinical benefit
• No human pharmacokinetic confirmation

10. Lee et al. (2025) — first IV human safety pilot

Best for: the only published human IV data Model: human pilot, n=2 healthy adults Standout finding: no adverse events at 10 mg IV day 1 and 20 mg IV day 2

This 2025 pilot dosed two healthy adults (one 58-year-old male, one 68-year-old female) with one-hour IV BPC-157 infusions on consecutive days. Vital signs, ECG, comprehensive metabolic panel, and thyroid function were monitored. No clinically meaningful changes appeared, and plasma concentrations returned to baseline within 24 hours (Lee et al., 2025).

It is the only published human IV BPC-157 study as of May 2026. The Office of Dietary Supplements and Anti-Doping policy still treats BPC-157 as unapproved and prohibited in sport (OPSS, 2024).

Strengths

• First published IV human safety data
• Full biomarker panel monitored

Limitations

• n=2 cannot establish population-level safety
• No efficacy endpoint, no placebo control

Bottom line

The BPC-157 evidence base is broader than skeptics claim and narrower than vendors imply. Animal data is consistent across tendon, ligament, gut, and skin models, mostly from one research group in Zagreb. Human data is limited to fewer than 30 total subjects across all published pilots as of 2026.

This is not informed consent for self-experimentation. The FDA has not approved BPC-157 for any indication, and the Office of Dietary Supplements lists it as a prohibited and unapproved drug. Talk to a licensed clinician before considering any peptide.

Related Reading

• Compounded peptides vs research chemicals: 10 key differences (2026)
• Where to buy peptides legally in 2026
• BPC-157 for tendon healing: animal study review

Frequently asked questions

Are there any large human trials of BPC-157? No. As of May 2026, only three small human pilot studies have been published, with fewer than 30 total subjects. None are randomized controlled trials and none have placebo controls.

Is BPC-157 FDA-approved? No. BPC-157 is not approved for any medical indication. The FDA classified it in Category 2 in 2023, meaning bulk substance compounding is not allowed pending further safety review.

Why is most BPC-157 research from one lab? The Zagreb research group led by Predrag Sikiric has published the bulk of the BPC-157 literature since the 1990s. Independent replication outside that program is limited, which is a known concern in the evidence base.

Does BPC-157 work in humans the way it works in rats? Unknown. Animal pharmacokinetics and tissue response do not always translate. The 2025 IV pilot showed no acute safety signals in two healthy adults but did not test efficacy.

Is BPC-157 legal to buy? It is sold online labeled "for research use only" but is not legal to compound for human use in the US. The World Anti-Doping Agency prohibits BPC-157 in sport at all times.

---

Researched and drafted by Theo Park, an AI editorial persona at Peptide Front, against published sources. Reviewed by our editorial team.